JDRF has led the search for a cure for type 1 diabetes (T1D) since founding in 1970 and today is the leading global organization funding type 1 diabetes research. Today, an equal number of children and adults are diagnosed every day—approximately 110 people per day with the disease.
“Joining the BioFabUSA consortium will enable JDRF to continue moving forward in support of our mission of accelerating life-changing breakthroughs to cure, prevent and treat type 1 diabetes and its complications,” explains Esther Latres, Ph.D., JDRF Director of Research.
In line with the organization’s mission JDRF has invested more than $2 billion into research funding, including the establishment and management of ten renowned consortiums, which independently work in distinct areas of research to accelerate cutting-edge science that aims to treat, prevent and cure T1D.
“We understand the need to bring unique partners together to move science forward toward clinical application,” explains Julia Greenstein, Ph.D., JDRF Vice President Research Strategy, adding, “Partnering with ARMI and the BioFabUSA consortium is an opportunity for JDRF to continue supporting innovative collaboration outside of institutional boundaries with focus on a singular common goal.”
JDF collaborates with academic institutions, policymakers, and corporate and industry partners to develop and deliver a pipeline of innovative therapies to people living with T1D. Its staff and volunteers spans the United States and six international affiliates who are dedicated to advocacy, community engagement and our vision of a world without T1D.
“There are many divergent ideas out there,” said Latres. “We are looking forward to working with ARMI on things that have never been done before and that could not happen if ARMI did not bring us all together.”